IGC Pharma Inc

IGS1

Company Profile

  • Business description

    IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer’s disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer’s disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer’s. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

  • Contact

    10224 Falls Road
    PotomacMD20854
    USA

    T: +1 301 983-0998

    E: [email protected]

    https://www.igcinc.us

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 March 2026

    Employees

    67

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,774.8086.801.00%
CAC 407,615.9978.421.04%
DAX 4023,644.21375.201.61%
Dow JONES (US)43,011.75429.971.01%
FTSE 1008,758.990.950.01%
HKSE24,177.07487.942.06%
NASDAQ19,905.30274.331.40%
Nikkei 22538,790.56436.471.14%
NZX 50 Index12,467.4865.17-0.52%
S&P 5006,084.2959.120.98%
S&P/ASX 2008,555.5080.600.95%
SSE Composite Index3,420.5738.981.15%

Market Movers